4 Blockbuster Drug Launches to Watch in 2019

Get ready for some blockbuster drug launches that could get intense.

Clarivate Analytics has offered a report on experimental drugs entering the market soon that are expected to generate sales above $1 billion in 2023. Every potential blockbuster is important to the company that launches it, but there are a few in the annual Clarivate report that are more important than usual. In 2019, AbbVie (NYSE: ABBV), Alexion Pharmaceuticals (NASDAQ: ALXN), and Aimmune Therapeutics (NASDAQ: AIMT) face upcoming drug launches that they can't afford to fumble.